Huang Yiyong, Lv Xiaolan, Si Tao, Meng Xia, Liao Xiaolin, Zhang Pengfei, Peng Zheng, Zhou Zheyi, Yi Ping, Huang Shigao
Department of Clinical Laboratory, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi, China.
Department of Clinical Laboratory, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou, Guangxi, China.
Front Immunol. 2025 Jul 4;16:1610296. doi: 10.3389/fimmu.2025.1610296. eCollection 2025.
Radiotherapy, as a key component of the comprehensive treatment system for malignant tumors, not only facilitates precise tumor destruction but also necessitates the strategic use of radioprotective agents to regulate immune responses and mitigate toxicity in normal tissues. Revealing the molecular biological mechanisms of ionizing radiation damage, such as DNA double-strand breaks, oxidative stress responses, and abnormal cell cycle regulation is critical for the development of clinically effective radioprotective drugs. Such advancements hold dual significance in enhancing patient outcomes and improving clinical efficacy. This paper explores the classification of radioprotective agents, and their diverse mechanisms of action, including free radical scavenging, regulation of redox enzyme systems, suppression of ionizing radiation-induced inflammation, and apoptosis-related immune damage. And, it also examines the challenges and prospects of their clinical translation. This study aims to provide important theoretical framework for the development of radioprotective agents to contribute to future advancements in radiation therapy.
放射治疗作为恶性肿瘤综合治疗体系的关键组成部分，不仅有助于精确摧毁肿瘤，还需要战略性地使用辐射防护剂来调节免疫反应并减轻正常组织中的毒性。揭示电离辐射损伤的分子生物学机制，如DNA双链断裂、氧化应激反应和异常细胞周期调控，对于开发临床有效的辐射防护药物至关重要。这些进展在提高患者治疗效果和临床疗效方面具有双重意义。本文探讨了辐射防护剂的分类及其多样的作用机制，包括自由基清除、氧化还原酶系统调节、抑制电离辐射诱导的炎症以及凋亡相关的免疫损伤。此外，还研究了其临床转化面临的挑战和前景。本研究旨在为辐射防护剂的开发提供重要的理论框架，以推动放射治疗的未来发展。
